CRISPR-Edited Stem Cells Shield Healthy Blood Cells While Attacking Leukemia
A 30-patient trial shows CRISPR-deleted CD33 donor stem cells survive transplant and may allow safer CAR-T therapy for AML and MDS.
Summary
Researchers at Washington University used CRISPR to remove the protein CD33 from donor stem cells before transplanting them into patients with acute myeloid leukemia and myelodysplastic syndrome. The problem with treating these aggressive blood cancers is that CAR-T therapies targeting cancer cells also destroy healthy blood stem cells carrying the same protein. By editing donor cells to lack CD33, the healthy transplanted cells become invisible to CD33-targeted treatments. In a 30-patient clinical trial across 15 sites in the US and Canada, the edited cells successfully engrafted and appeared to protect healthy blood cells. The results, published in Nature Medicine, suggest this approach could be combined with CD33-targeted CAR-T therapy in future trials, potentially making treatment both safer and more effective for cancers that currently have very limited options after transplant failure.
Detailed Summary
Acute myeloid leukemia and myelodysplastic syndrome are among the most difficult blood cancers to treat. Stem cell transplantation offers a potential cure, but when cancer returns after transplant, physicians face a near-dead-end. CAR-T cell therapy, which has revolutionized treatment of some blood cancers, largely fails here because the protein targets on cancer cells also appear on healthy donor stem cells, causing collateral destruction and weakening treatment efficacy.
A team at Washington University School of Medicine developed a workaround using CRISPR gene editing. Before transplantation, donor stem cells were edited to remove CD33, a protein expressed on both AML and MDS cancer cells and healthy myeloid cells. The logic: if healthy transplanted cells no longer carry CD33, a CD33-targeted therapy can hunt cancer cells without friendly-fire destruction of the donor graft.
In a 30-patient clinical trial conducted at Siteman Cancer Center and 14 additional US and Canadian sites, the CD33-deleted donor stem cells successfully engrafted and produced normal blood cell populations. Outcomes looked comparable to standard stem cell transplantation, a meaningful safety signal. One separately reported case involved a high-risk AML patient who received the edited transplant followed by CD33-targeted immunotherapy, hinting at the combined strategy's potential.
The findings, published in Nature Medicine, represent a clinically significant proof of concept. The approach directly addresses one of oncology's most stubborn engineering problems: how to give a targeted therapy a clean shot at cancer when the target is shared with essential healthy tissue. Similar logic could extend to other shared antigens beyond CD33.
Caveats remain. The trial was not designed to test combined CRISPR-transplant plus CAR-T therapy; that step awaits future trials. Long-term durability of the edited graft and whether CD33 deletion affects normal immune function over years are still open questions. Nevertheless, this work marks a concrete advance toward making curative-intent therapy accessible for patients who currently have almost no options after relapse.
Key Findings
- CRISPR deletion of CD33 from donor stem cells allowed successful engraftment in 30 patients with AML or MDS.
- Edited cells appeared to protect healthy transplanted blood cells from CD33-targeted cancer therapies.
- Outcomes of the CD33-deleted transplant were comparable to standard stem cell transplantation in safety signals.
- The strategy could allow future combination of CRISPR-edited transplants with CD33-targeted CAR-T therapy.
- One high-risk AML case demonstrated feasibility of pairing the edited transplant with CD33-directed immunotherapy.
Methodology
This is a news report summarizing a published clinical trial in Nature Medicine, a high-credibility peer-reviewed journal. The study involved 30 patients across 15 sites in the US and Canada, providing multi-center evidence. It is a phase I/II-style safety and feasibility trial, not a randomized controlled trial, so efficacy conclusions are preliminary.
Study Limitations
The trial assessed engraftment and safety but was not powered or designed to demonstrate survival or remission benefits of combined CRISPR-plus-CAR-T therapy. Long-term consequences of CD33 deletion on immune function and graft durability are unknown. Only a single case report has tested the full combined strategy; larger controlled trials are needed before clinical adoption.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: